To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

NCT05581199 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

DRUG: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
DRUG: Batoclimab 340 mg SC weekly
DRUG: Placebo

Sponsor

Immunovant Sciences GmbH